Details:
Macuneos (BIO201) is an orally administered small molecule in development for the treatment of diseases of the retina, or retinopathies. Biophytis has completed preclinical cellular and animal studies of Macuneos (BIO201) for the treatment of retinopathies.
Lead Product(s): BIO201
Therapeutic Area: Ophthalmology Product Name: Macuneos
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: BPI
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Funding April 29, 2021